TRATAMENTO INTERVENCIONISTA NA PSORÍASE: IMPACTOS NA QUALIDADE DE VIDA E SAÚDE GERAL

Authors

  • Yuji Atarashi Tavares Universidade do Vale do Sapucaí
  • Daniel Felipe Nobre Castiel UNIFACS
  • Leandro Aparecido Irrazabal UNIPAMPA
  • Roberto Tavares Carreiro UNB
  • Aliandro Willy Duarte Magalhães Centro Universitário do Estado do Pará
  • Nicole Eberle UNISINOS
  • Ana Luiza Ferretto Jaenisch PUCRS
  • Gabriela Nairana Pedroso Mrozinski UFN
  • Poliana Höhl de Paiva Universidade Evangélica de Goiás
  • Felipe de Assis Rocha Lima Faculdade Pernambucana de Saúde (FPS)
  • Isadora Leticia Petry UNISINOS
  • Caio Fernando Lima Ribeiro Universidade Federal do Pará
  • Ana Paula Da Silva Mendes Universidade José do Rosário Vellano - UNIFENAS
  • Daniel de Souza Matos Vital UNB
  • Denise dos Santos Moitinho Universidad Maria Serrana
  • Bianca Almeida Pessoa Rodrigues de Araújo UESPI

DOI:

https://doi.org/10.36557/2674-8169.2024v6n10p4197-4210

Keywords:

Psoriasis, Dermatology, Treatment

Abstract

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by the formation of scaly, red plaques, resulting from an acceleration of the cell renewal cycle. Although often considered solely a dermatological issue, psoriasis has profound impacts on patients' quality of life, affecting not only physical health, but also emotional and social well-being. Therefore, interventional treatment in psoriasis, which includes biological therapies and systemic medications, has been shown to be effective in reducing symptoms and improving the general health of individuals. Objective: To investigate the effects of interventional treatment on psoriasis, evaluating its implications on the quality of life and general health of patients. Methodology: The Cochrane, Scielo and Medline databases were used, searching for articles published between 2022 and 2024, in Portuguese or English. Final Considerations: Interventional treatment in psoriasis represents a significant advance in the approach to this complex and impactful condition. On the one hand, the effectiveness of biological and systemic therapies not only reduces cutaneous manifestations, but also improves patients' quality of life, allowing greater participation in social and professional activities. Furthermore, this adequate management of psoriasis contributes to mental health, reducing the stigma associated with the disease. Therefore, it is essential that patients receive continuous support and medical monitoring, ensuring that interventions are personalized and effective.

Downloads

Download data is not yet available.

References

AL-HOMOOD, I. A. et al. Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting. Advances in Rheumatology, v. 64, n. 1, 29 abr. 2024.

BENITES, E.; CARRILLO, E.; HERAS, M. Effects of methotrexate and etanercept treatment in moderate and severe psoriasis. Medicine (Baltimore), p. e31527–e31527, 2022.

BISSONNETTE, R. et al. An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis. The New England Journal of Medicine, v. 390, n. 6, p. 510–521, 8 fev. 2024.

CAI, L. et al. A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 15 fev. 2024.

FARINA, C. J. et al. Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. Cardiovascular research, 25 mar. 2024.

GEBAUER, K. et al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. Journal of the American Academy of Dermatology, v. 91, n. 1, p. 91–99, 1 jul. 2024.

KIRCIK, L. H. et al. Preference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis. Journal of Drugs in Dermatology, v. 23, n. 8, p. 607–611, 1 jul. 2024.

PAPP, K. A. et al. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatology, 20 dez. 2023.

VIEIRA, M. et al. Dermoscopy as an auxiliary tool for the diagnosis of acral squamous diseases: palmoplantar psoriasis, tinea pedis/manuum and eczema. Anais Brasileiros de Dermatologia, 1 abr. 2024.

WARREN, R. B. et al. Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS). Journal of the American Academy of Dermatology, 1 nov. 2023.

Published

2024-10-28

How to Cite

Atarashi Tavares, Y., Felipe Nobre Castiel, D., Aparecido Irrazabal, L., Tavares Carreiro, R., Willy Duarte Magalhães, A., Eberle, N., Ferretto Jaenisch, A. L., Nairana Pedroso Mrozinski, G., Höhl de Paiva, P., de Assis Rocha Lima , F., Leticia Petry, I., Fernando Lima Ribeiro, C., Da Silva Mendes, A. P., de Souza Matos Vital, D., dos Santos Moitinho, D., & Almeida Pessoa Rodrigues de Araújo, B. (2024). TRATAMENTO INTERVENCIONISTA NA PSORÍASE: IMPACTOS NA QUALIDADE DE VIDA E SAÚDE GERAL. Brazilian Journal of Implantology and Health Sciences, 6(10), 4197–4210. https://doi.org/10.36557/2674-8169.2024v6n10p4197-4210